Bictegravir/Emtricitabine/Tenofovir Alafenamide in Pregnant Women Infected with HIV-1: Real-Life Use

Bictegravir/Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) is a convenient, well-tolerated, once-daily, and single-tablet regimen. There are few data on its use during pregnancy. The primary objective was to evaluate the efficacy of BIC/FTC/TAF at delivery, defined as a plasma viral load <50 cp/mL. We conducted a retroprospective, single-center study including pregnant women living with HIV-1 who were on BIC/FTC/TAF. From January 2020 to January 2023, 12 women living with HIV-1 received BIC/FTC/TAF during pregnancy and at delivery. Two were receiving BIC/FTC/TAF at conception and remained on the same combination antiretroviral therapy (cART) throughout the pregnancy, and 10 received BIC/FTC/TAF at least during the third trimester and at delivery. Ten had a plasma viral load <50 cp/mL at delivery. The two who were not suppressed at delivery reported nonadherence to BIC/FTC/TAF, which was not related to treatment side effects. Reported tolerance was good. BIC/FTC/TAF might be a good option during pregnancy and particularly to simplify previous cART but it is necessary to counsel patients to ensure good adherence to this one.